Benefits
Same-day cognitive benefits under stress
A 2025 randomized, double-blind, placebo-controlled crossover study confirmed Zensera™ delivers measurable cognitive performance improvements on the same day of first use — an acute onset rate that positions it alongside Zynamite® S and FastBliss® as a fast-acting cognitive ingredient. The specific cognitive domains improved and the measurement battery used are detailed in the published Givaudan clinical data.
Emotional balance and stress resilience
Zensera™ supports emotional balance under stress conditions — improving the stress-cognitive interface where chronic stress impairs working memory, executive function, and decision-making. By reducing the neurological impact of acute stress on cognitive performance, Zensera™ helps maintain mental clarity during demanding situations.
Dual acute and ongoing cognitive support
Beyond same-day effects, Zensera™ provides sustained cognitive and emotional balance benefits with regular use — addressing both acute performance demands and the longer-term cognitive resilience that builds with consistent stress management support.
Mechanism of action
Stress-cognitive pathway botanical modulation
Zensera™'s proprietary botanical extract targets the neurological pathways connecting stress response activation to cognitive performance impairment — likely through HPA axis modulation, cortisol-cognitive signaling, and/or direct neurotransmitter balance effects that maintain cognitive function under stress conditions. Specific mechanism details available through Givaudan Active Beauty technical documentation.
Clinical trials
Randomized, double-blind, placebo-controlled crossover study demonstrating Zensera™ delivers same-day cognitive benefits and supports emotional balance under stress.
106 healthy young adults with moderate subjective stress. Randomized, double-blind, placebo-controlled, parallel-group design. 300 mg Zensera™ (Givaudan patent-pending lemon balm extract from Melissa officinalis L.) vs matching placebo. Cognitive function, mood, heart rate and BP measured at baseline, 1, 3, and 5 hours post-treatment during cognitive overload tasks. NCT06183372 (LemCog trial, University of Reading).
Primary outcome (overall calmness) was not significant. SECONDARY findings: at 5 hours post-consumption, Zensera improved performance on the most demanding cognitive challenges vs placebo. Performance gains correlated with increased calmness and contentment, suggesting same-day cognitive performance support lasting at least 5 hours. Published in Therapeutic Advances in Psychopharmacology (DOI 10.1177/20451253261415706, Feb 2026; PubMed indexing pending). Mechanism: GABA receptor activation + GABA transaminase inhibition, plus rosmarinic acid bioavailability. Supports broader lemon balm class evidence in PubMed: Scholey 2014 anti-stress foods (PMID 25360512), Kennedy 2002 mood/cognition (PMID 12062586) and 2003 dose-response (PMID 12888775).